论文部分内容阅读
Over 70%of human breast cancer expresses estrogen receptor(ER)and selective estrogen receptor modulators(SERMs),such as tamoxifen,have been widely used in their treatments.Unfortunately,up to half of the patients are or soon become resistant to the therapy.Hence,further development of novel strategies to selectively block the activities of this pathway is urgently needed.